Baxiva AG
Startup Plus
Baxiva is an ETH Zurich spin-off developing a VLP-based platform for potent, highly multivalent glycoconjugate vaccines against bacterial infections. Supported by CARB-X, our lead programme is the world’s first ExPEC/UTI vaccine to target the bacterial capsule, designed to prevent recurrent urinary tract infections and life-threatening complications including sepsis. Baxiva is seeking investors and strategic partners to advance the programme towards clinical development.
Stay up-to-date
Join our mailing list to receive exclusive content and offers.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events